1
|
Patt A, Demoret B, Stets C, Bill KL, Smith P, Vijay A, Patterson A, Hays J, Hoang M, Chen JL, Mathé EA. MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models. Cancers (Basel) 2020; 12:cancers12082157. [PMID: 32759684 PMCID: PMC7463633 DOI: 10.3390/cancers12082157] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 07/22/2020] [Accepted: 07/30/2020] [Indexed: 01/01/2023] Open
Abstract
Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS patients with higher MDM2 amplification have lower chemotherapy sensitivity and worse outcome than patients with lower MDM2 amplification. We hypothesized that MDM2 amplification levels may be associated with changes in DDLPS metabolism. Six patient-derived DDLPS cell line models were subject to comprehensive metabolomic (Metabolon) and lipidomic (SCIEX 5600 TripleTOF-MS) profiling to assess associations with MDM2 amplification and their responses to metabolic perturbations. Comparing metabolomic profiles between MDM2 higher and lower amplification cells yielded a total of 17 differentially abundant metabolites across both panels (FDR < 0.05, log2 fold change < 0.75), including ceramides, glycosylated ceramides, and sphingomyelins. Disruption of lipid metabolism through statin administration resulted in a chemo-sensitive phenotype in MDM2 lower cell lines only, suggesting that lipid metabolism may be a large contributor to the more aggressive nature of MDM2 higher DDLPS tumors. This study is the first to provide comprehensive metabolomic and lipidomic characterization of DDLPS cell lines and provides evidence for MDM2-dependent differential molecular mechanisms that are critical factors in chemoresistance and could thus affect patient outcome.
Collapse
Affiliation(s)
- Andrew Patt
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA;
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, 9800 Medical Center Dr., Rockville, MD 20892, USA
- Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA
| | - Bryce Demoret
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; (B.D.); (C.S.); (K.-L.B.); (J.H.); (M.H.)
| | - Colin Stets
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; (B.D.); (C.S.); (K.-L.B.); (J.H.); (M.H.)
| | - Kate-Lynn Bill
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; (B.D.); (C.S.); (K.-L.B.); (J.H.); (M.H.)
| | - Philip Smith
- The Huck Institutes of Life Sciences, Penn State University, State College, PA 16802, USA; (P.S.); (A.V.); (A.P.)
| | - Anitha Vijay
- The Huck Institutes of Life Sciences, Penn State University, State College, PA 16802, USA; (P.S.); (A.V.); (A.P.)
| | - Andrew Patterson
- The Huck Institutes of Life Sciences, Penn State University, State College, PA 16802, USA; (P.S.); (A.V.); (A.P.)
| | - John Hays
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; (B.D.); (C.S.); (K.-L.B.); (J.H.); (M.H.)
| | - Mindy Hoang
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; (B.D.); (C.S.); (K.-L.B.); (J.H.); (M.H.)
| | - James L. Chen
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; (B.D.); (C.S.); (K.-L.B.); (J.H.); (M.H.)
- Correspondence: (J.L.C.); (E.A.M.)
| | - Ewy A. Mathé
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA;
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, 9800 Medical Center Dr., Rockville, MD 20892, USA
- Correspondence: (J.L.C.); (E.A.M.)
| |
Collapse
|